Navigation Links
Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
Date:6/5/2011

EAST HANOVER, N.J., June 5, 2011 /PRNewswire/ -- Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking Gleevec® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment. These data will be presented at the 47th American Society of Clinical Oncology (ASCO) plenary session on Sunday, June 5.

The results show that at five years 66% of patients taking Gleevec for three years remained free of cancer recurrence (primary endpoint) compared to 48% who had received Gleevec for only one year (p<0.0001). Moreover, 92% of patients taking Gleevec for three years were alive (secondary endpoint) compared to 82% who had received Gleevec for only one year (p=0.019) (1). Median patient follow-up was 54 months.

The 400-patient Phase III trial, conducted by the Scandinavian Sarcoma Group (SSG) and the Sarcoma Group of the Arbeitsgemeinschaft Internistische Onkologie (AIO), is the first prospective multicenter clinical trial to demonstrate a survival benefit of adjuvant Gleevec therapy for KIT+ GIST with extended three years of therapy relative to one year of therapy. The side effect profile in the clinical trial was consistent with that reported in previous studies with Gleevec.

"This study confirms the hypothesis that extending the duration of Gleevec treatment for patients following surgery improves recurrence-free survival. For the first time, an effect on overall survival was found," said Heikki Joensuu, M.D., Ph.D., Professor, Oncology, University of Helsinki and principal investigator of the study. "Results from this trial may positively impact clinical practice by helping physicians create the optimal treatment plan for patients with operable KIT+ GIST."

Gastrointestinal stromal tumors are a rare, life-threatening cancer of the gastrointestinal
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
2. Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
3. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
4. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
5. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
6. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
7. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
8. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
9. Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
10. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
11. Final Approval of Novartis Gender Discrimination Settlement Slated for November 19
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... CHAPEL HILL, N.C. , July 11, 2014 ... research analysis approaches are evolving across industry sectors ... are now examining better ways to engage with ... how consumers inform themselves and make critical purchasing ... by benchmarking firm, Best Practices, LLC, one area ...
(Date:7/11/2014)... Research and Markets has announced ... X-ray Film Industry Report 2014" report to their ... Global And Chinese Medical X-Ray Film Industry Report ... current state of the Global medical X-ray film industry ... report provides a basic overview of the industry including ...
(Date:7/11/2014)... 11, 2014 Research and Markets  has ... Market 2014-2018" report to their offering. ... needle is a hollow needle commonly used with a ... to extract fluids from it. A hypodermic needle is ... substances that cannot be ingested. Hypodermic needles are broadly ...
Breaking Medicine Technology:New Technologies Transforming Consumer Marketing Research Playbook 2Global and Chinese Medical X-ray Film Industry Report 2014 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3
... BioTrends Research Group, Inc. recently published its ... is based on online survey ... radiologists and interventional nephrologists). It provides an in-depth view ... patterns related to both vascular access placement and maintenance. ...
... Aug. 24 Sunridge International (OTC Bulletin Board: ... next month to have meetings with key brokers and funds. ... to our company,s technology, and to facilitate funding for Sunridge ... "Now is a good time for this project," states G. ...
Cached Medicine Technology:Latest BioTrends Report Provides Comprehensive Market Landscape of the Dialysis Vascular Access Market 2
(Date:7/14/2014)... West Jordan, UT (PRWEB) July 14, 2014 ... with the inclusion of a new comprehensive cancer center ... Valley Medical Center will be the only hospital west ... inpatient and outpatient cancer services , Additionally, Jordan Valley ... develops healthcare products and cancer treatment planning systems for ...
(Date:7/14/2014)... The report “Intelligent Building Automation Technologies Market by ... Management], IT Technologies & Industry Verticals - Global ... defines and segments the IBAS market into various ... revenues. The report also identifies the factors driving ... along with the technology roadmap and adoption trends. ...
(Date:7/14/2014)... BCC Research ( http://www.bccresearch.com ) ... GLOBAL MARKETS , the global synthetic biology market ... in 2018, with a five-year compound annual growth ... the fastest growing segment, with anticipated $9.7 billion ... in the pharmaceutical/diagnostics, chemical, energy, and agricultural industries ...
(Date:7/14/2014)... Eye tests could be used to identify people in ... suggest. In one study, early results from 40 ... significant association between levels of beta-amyloid plaques in the ... in the brain. Beta-amyloid plaques in the brain are ... test could be used in conjunction with the brain ...
(Date:7/14/2014)... Amy Norton HealthDay Reporter ... who enjoy mentally stimulating games may have bigger brains and ... The study looked at the connection between playing games such ... adults in their 50s and 60s. Researchers found that ... performed better on tests of memory and other mental functions. ...
Breaking Medicine News(10 mins):Health News:Jordan Valley Medical Center Set to Break Ground with New $10 Million Cancer Center 2Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 2Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 3Health News:Eye Tests Might Help ID Alzheimer's, Studies Suggest 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 3
... one another could rewrite the textbooks on neuroscience, says a ... and Yale University. ,Their study, published as a ... key cellular enzyme called dynamin 1 is not essential to ... ,Dynamin has long been a focus of research for its ...
... pressure and additional risk factors for heart disease ... than two , if their current treatment combines ... medication amlodipine, researchers reported at the American Heart ... and Outcomes Research in Cardiovascular Disease and Stroke. ...
... and Family Welfare Minister, Dr. Anbumani Ramados, speaking ... today , said that under the National Rural ... 200,000 nursing personnel to provide comprehensive health care. ... requirements of NRHM, State Governments have been advised ...
... poignant emotions and subjects that are not often discussed ... the mainstay of the international film festival on gender ... first day Saturday. , ,Brought together by ... the Mac Arthur Foundation and UNESCO, the four-day festival ...
... Vietnam after it was first detected on a farm in ... Sunday. ,Nearly 1,300 ducks were found dead late last ... south of Hanoi, and tests showed they were positive to H5N1, ... Vietnam. ,The dead ducks were part of three flocks ...
... obsession with heights. In "Murder", "Gangster" and now "Metro", characters ... of skyscrapers. ,In "Metro", he even gets his ... And when it isn't guitars, it's Irrfan and Konkona getting ... ,It's meant to be therapeutic and we'll take Anurag Basu's ...
Cached Medicine News:Health News:Study Revises Dynamin's Role in Nerve Cell Function 2Health News:Study Revises Dynamin's Role in Nerve Cell Function 3Health News:One Pill may Be Better Than Two for Treating Patients With High Blood Pressure 2Health News:One Pill may Be Better Than Two for Treating Patients With High Blood Pressure 3Health News:Film Festival on Gender Sexuality Draws Crowds 2Health News:'Metro' - a Witty Look at Insensitivities of City Life 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: